Abstract
Multiple Sclerosis (MS) is a chronic disease characterized by a process of loss of the myelin sheath of neuronal axons. It is estimated that in 2020, there were 2.8 million people with MS worldwide. A promising pharmaceutical class that already has four drugs for MS treatment is S1P1 modulators class. The aim of this study was to conduct a technological prospecting, using patents and scientific articles related to the technological development of S1P1 modulators applied to the multiple sclerosis treatment. Novartis is the institution that has published the largest number of scientific publications in the area and, also, the one that has filed the largest number of patent applications. It was observed that, even the scientific research conducted by Novartis has an applied research character.
Publisher
South Florida Publishing LLC
Reference21 articles.
1. Bolli, M. et al. (2004) 5-(Benz-
2. (z) -ylidene) -thiazolidin-4-one derivatives as immunosuppressant agents (2004). Assignee: Actelion Pharmaceuticals Ltd. EP 1 689 726 B1. Filled on November 16th, 2004. Granted on October 6th, 2010.
3. Derwent Innovation Index. Clarivate. Available at https://www-webofscience.ez140.periodicos.capes.gov.br/wos/diidw/basic-search. Accessed in November 2023.
4. Espacenet. European Patent Office. Available at https://worldwide.espacenet.com/patent/search. Accessed in November 2023.
5. Faissner, S. et al. (2019). Progressive multiple sclerosis: from pathophysiology to therapeutic strategies. Nature Reviews: Drug Discovery,18, 905-922. DOI:10.1038/s41573-019-0035-2